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Abstract
Skin and chronic wound infections caused by highly antibiotic resistant bacteria such as methicillin-resistant Staphylococcus
aureus (MRSA) are an increasing and urgent health problem worldwide, particularly with sharp increases in obesity and
diabetes. New Zealand manuka honey has potent broad-spectrum antimicrobial activity, has been shown to inhibit the
growth of MRSA strains, and bacteria resistant to this honey have not been obtainable in the laboratory. Combinational
treatment of chronic wounds with manuka honey and common antibiotics may offer a wide range of advantages including
synergistic enhancement of the antibacterial activity, reduction of the effective dose of the antibiotic, and reduction of the
risk of antibiotic resistance. The aim of this study was to investigate the effect of Medihoney in combination with the widely
used antibiotic rifampicin on S. aureus. Using checkerboard microdilution assays, time-kill curve experiments and agar
diffusion assays, we show a synergism between Medihoney and rifampicin against MRSA and clinical isolates of S. aureus.
Furthermore, the Medihoney/rifampicin combination stopped the appearance of rifampicin-resistant S. aureus in vitro.
Methylglyoxal (MGO), believed to be the major antibacterial compound in manuka honey, did not act synergistically with
rifampicin and is therefore not the sole factor responsible for the synergistic effect of manuka honey with rifampicin. Our
findings support the idea that a combination of honey and antibiotics may be an effective new antimicrobial therapy for
chronic wound infections.
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Introduction
Infectious diseases continue to take a toll on human health and
life expectancy. In the western world, increased longevity and
health complications due to the sharp rise in obesity and diabetes
have made chronic wound infections particularly problematic. In
the United States, chronic wounds affect 6.5 million patients and
are estimated to cost US$25 billion annually, with significant
increases expected in the future [1]. Treatment of these infections
is becoming increasingly difficult due to antibiotic resistance to
currently available drugs [2]. Staphylococcus aureus is the causative
agent of many serious acute and chronic skin infections and is one
of the most predominant wound pathogens [3,4,5]. Strains of
methicillin-resistant S. aureus (MRSA) have become increasingly
common and the spread of these represents a serious health threat
[6]. Commercial development of new classes of antibiotics has
diminished over the past 15 years and few pharmaceutical
companies remain active in this area [7]. There is an urgent need
for new approaches to treat these infections.
To combat antibiotic resistance, combination antibiotic treat-
ment is widely practiced in the clinic. Such treatment can result in
synergism to provide increased efficacy and a reduction in amount
of each antibiotic used, which can reduce the risk of possible side
effects and treatment costs [8,9,10,11]. Moreover, combination
use of antibiotics with different modes of action reduce the risk of
antibiotic resistance arising during therapy [12,13]. This is
particularly important for chronic wounds where antibiotic
therapy is often long-term.
Given the difficulty in treating infected chronic wounds due to
multi-resistant bacteria, honey is increasingly being used as a
topical treatment for these wounds. There are several reports of its
successful application in the treatment of chronic wound infections
not responding to antibiotic therapy [14]. The major honey in
medical use today, manuka honey, is available in various licensed
dressings and is sourced from the New Zealand manuka tree
Leptospermum scoparium. Manuka honey has broad-spectrum anti-
bacterial activity [15,16,17,18] and is effective against antibiotic-
resistant wound pathogens [17,19,20]. Furthermore, no resistant
bacteria could be isolated after exposure of wound isolates
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(Escherichia coli, MRSA, Pseudomonas aeruginosa, and Staphylococcus
epidermidis) to sub-inhibitory concentrations of manuka honey
[20,21]. This is believed to be due to the fact that manuka honey
contains a range of antibacterial constituents including methyl-
glyoxyl (MGO) [22,23]; hydrogen peroxide [24,25,26], and other
active substances that are yet to be defined [26].
The broad-spectrum antibiotic rifampicin is commonly used in
the treatment of staphylococcal prosthesis- or skin-associated
infections, including chronic wounds [27,28]. The chemical
structure of rifampicin allows this drug to penetrate well into
tissues and abscesses, which are poorly penetrated by most other
anti-staphylococcal agents [29,30]. However, S. aureus can develop
rifampicin resistance during a single passage [29], and it is
therefore always used in combination with other antibiotics to
treat bacterial infections [30,31,32,33]. The development of
resistance to rifampicin in bacteria is typically due to a single,
but variable, point mutation in its target, the b subunit of bacterial
RNA polymerase [34,35,36]. Although rifampicin combination
therapy has been demonstrated to be effective against severe
staphylococcal infections, rifampicin resistance can still emerge
[37].
A combination of the antimicrobial properties of clinically
approved antibiotics and the antibacterial activity of manuka
honey could lead to a new spectrum of antimicrobials that have
the potential to prevent the emergence of resistant bacterial
strains, providing broad-spectrum coverage and consequently
improving therapeutic efficiency. In this study, we show a
synergistic effect between rifampicin and commercially available
FDA-approved manuka honey, Medihoney (Comvita, NZ) on
clinical S. aureus isolates, including MRSA strains. Unlike with
rifampicin alone, in which resistance was observed after overnight
incubation on plates, the combination of Medihoney and
rifampicin maintained susceptibility of S. aureus to rifampicin.
We also show that MGO is not solely responsible for the observed
synergistic action between rifampicin and Medihoney. This study
highlights the potential of a combinational use of Medihoney and
rifampicin to develop novel therapies for chronic wounds and
serious skin infections, to both improve efficacy and reduce the risk
of antibiotic resistance.
Materials and Methods
S. aureus strains, Media and Antibiotics
Laboratory strain S. aureus NCTC8325 and several S. aureus
clinical isolates were used in this study. The latter included non-
MRSA strains, 04-229-2455 and 04-227-3567 and MRSA strains,
IMVS67 (nmMRSA D), MW2 (USA400, CA-MRSA), and
RPAH18 (Aus-2) (kindly provided by Dr. Jon Iredell, Westmead
Hospital, Sydney) and USA300 (CA-MRSA) (kindly provided by
Dr. Barry Kreiswirth, Public Health Research Institute Center,
Newark, NJ). All growth assays were set up in cation-adjusted
Mueller Hinton II Broth (CaMHB, Becton Dickinson). Rifampi-
cin, oxacillin and methyglyoxal (MGO; 40% w/v in water) were
obtained from Sigma-Aldrich.
Honey
Two types of honeys were used in this study: commercially
available active manuka honey in a proprietary formulation
(Medihoney, Comvita Ltd, NZ) [20,38,39] and manuka honey
sourced from Leptospermum scoparium plantations in Hokianga, NZ
(provided by Comvita Ltd, NZ). Honey concentrations are
reported here as % weight/volume. MGO levels were determined
during the study to be 958 mg/kg for manuka honey and 781 mg/
kg for Medihoney (Comvita Ltd, NZ) [40]. A sugar solution
containing 7.5 g sucrose, 37.5 g maltose, 167.5 g glucose, 202.5 g
fructose (all from Sigma-Aldrich) in 85 mL sterile deionised water
was used to mimic the sugar content of honey.
Determination of Minimal Inhibitory Concentration (MIC)
in Microtiter Plates
MGO and honey were diluted in CaMHB. Honey concentra-
tions, varying by 1% (range 1–32%), were used in successive wells.
Microtiter plates were then inoculated with approximately
107 CFU/mL (determined by CFU counting) of S. aureus. The
MIC of rifampicin was determined by serial doubling dilution with
DMSO. Final concentrations of 2% DMSO in CaMHB were used
in the experiments. Controls included a serial dilution of
lincomycin (to assess plate-to-plate variation), a positive control
with bacteria alone in CaMHB (with 2% DMSO for rifampicin)
and a negative control (no bacteria) with CaMHB (containing 2%
DMSO for rifampicin). Plates were incubated at 37uC for 22 h
and the 595 nm was measured using a Synergy HT Bio-Tek plate
reader. The MICs were defined as the lowest concentration of
rifampicin, MGO, and honey (alone or in combination) that
inhibited growth by 99.9% compared to the no-treatment control.
Checkerboard Microdilution Assay
Rifampicin was serially diluted in DMSO and each dilution was
added, in duplicate, to a 96-well plate to a final DMSO
concentration of 2%. MGO was diluted in CaMHB. Prior to
the addition of bacteria to the wells, a 50% honey solution in
CaMHB was prepared, and serial dilutions were made. Then, an
overnight culture of S. aureus NCTC8325 was diluted and
approximately 107 CFU/mL were added to each well. Plates
were handled as described above. Each experiment was performed
in duplicate three times on different days.
The fractional inhibitory concentration index (FICI) was
calculated as the sum of the MIC of each compound when used
in combination divided by the MIC of the compound used alone.
Synergy and antagonism were defined by an FICI of #0.5 and
.4, respectively. An FIC index of .0.5 but #4 was considered
indifferent [41,42].
Agar Diffusion Test
Fifty mL aliquots of 109 CFU/mL overnight culture of each of
the S. aureus strains were spread uniformly onto tryptic soy broth
agar (TSA, Oxoid) with or without 5% honey (or sugar solution) in
60615 mm tissue culture plates (Falcon). Paper discs impregnated
with 4 mg of each antibiotic were then placed onto the agar
surface. Inhibition zones were measured after incubation at 37uC
for 24 h. Assays were performed three times in duplicate. In order
to determine the effect of honey alone, bacterial CFUs were
determined by a standard plate count method as follows. Twenty
mL of overnight culture (approximately 16109 CFU/mL) were
diluted in 180 mL of PBS, followed by further serial dilution (1021
to 1028). Twenty mL of each dilution was then spotted onto a
freshly prepared TSA plate with or without 5% honey (in
triplicate). Colonies were counted after incubation at 37uC for
24 h, and CFUs determined.
Time-kill Curves
An exponentially growing culture of S. aureus NCTC8325 was
diluted to 16107 CFU/mL in CaMHB for inoculation. The test
concentrations were 0.2 mg/mL rifampicin, 7% Medihoney,
70 mg/mL MGO, 70 mg/mL MGO in a sugar solution corre-
sponding to 7% honey (MGOS), a combination of 0.2 mg/mL of
rifampicin and 7% Medihoney, a combination of 0.2 mg/ml of
Synergism between Medihoney and Rifampicin
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rifampicin and 70 mg/ml MGO, and a combination of 0.2 mg/ml
of rifampicin and 70 mg/ml MGOS. At pre-determined time
points (0, 2, 4, 8, 12, 24 and 48 h after incubation with agitation at
37uC) a 20 mL aliquot was removed from each culture and serially
diluted 10-fold in CaMHB. The dilutions were used for CFU
counting as described above except TSA plates without honey
were used. Synergism and antagonism were defined as either an
increase or decrease, respectively, of $2 log10-CFU/mL in
antibacterial activity produced by the combination compared to
that by the more active agent alone after 24 h, while a change of
,2 log10 CFU/mL was considered indifferent [43]. All CFU
counting was done in duplicate. All statistical analyses were
performed with GraphPad Prism Statistical Software 6.0 (Graph-
Pad Software, Inc. La Jolla, Ca).
Results
Synergistic Activity between Medihoney and Rifampicin
The antimicrobial activity of Medihoney and manuka honey
was confirmed by determining the minimum inhibitory concen-
tration (MIC) against S. aureus NCTC8325. Both honeys gave an
MIC of 8% (w/v). The MIC of rifampicin was 0.039 mg/mL
(Table S1). The MICs of rifampicin and Medihoney for the
clinical isolates (including MRSA strains) were similar, ranging
from 6–8% honey and 0.039–0.078 mg/mL rifampicin (Table S1)
and are comparable to MICs reported in the literature [44,45,46].
To test whether there was any synergy between rifampicin and
Medihoney on S. aureus a checkerboard microdilution assay was
performed. The results of the checkerboard analysis are summa-
rized in Table 1. An increased sensitivity against rifampicin was
observed in combination with Medihoney against the laboratory S.
aureus strain NCTC8325 and both MRSA (RPAH18, IMVS67
and MW2) and non-MRSA (04-227-3567) clinical isolates. The
corresponding FICIs were #0.5 in all tested strains (Table 1),
demonstrating a synergistic effect [41,42]. A synergistic effect was
also seen with manuka honey and rifampicin (FIC#0.5; Table 1).
However, rifampicin in combination with the sugar solution was
not synergistic (data not shown).
To confirm the synergistic activity between rifampicin and
Medihoney, time-kill experiments were performed (Fig. 1A). With
an initial inoculum of 107 CFU/mL, 7% Medihoney alone (sub-
MIC level) slowed down bacterial growth. However, growth of
bacteria then increased and by 24 h, bacterial growth in the
presence of 7% Medihoney was at the same level as no treatment.
Rifampicin alone also completely inhibited bacterial growth up to
8 h of incubation. However, even at 0.2 mg/mL (,56MIC) the
CFU/mL count increased dramatically after 8 h to levels of
growth similar to that observed in the untreated cultures at 24 h.
This is due to the attainment of resistance to this antibiotic by S.
aureus (see below). A combination of 7% Medihoney and 0.2 mg/
mL rifampicin yielded a.2-log10 decrease in CFU/mL compared
to rifampicin or Medihoney alone, and this was sustained up to
48 h (Fig. 1A). This is considered to be a synergistic activity [43].
Similar results were observed with rifampicin plus manuka honey
at the same concentrations (data not shown).
Agar disc diffusion tests were performed to visualize the
synergistic interaction between rifampicin and Medihoney with
S. aureus (Fig. 1B). The mean diameter of the inhibitory zone for
4 mg rifampicin on a filter disc was 20 mm on TSA plates and
18 mm on TSA plates with 5% sugar solution. This zone of
inhibition increased markedly to 41 mm and 38 mm on TSA
plates containing 5% Medihoney and 5% manuka honey,
respectively. All clinical isolates of S. aureus tested, including the
MRSA strains, gave similar results (Fig. 1C). To test whether
honey alone was responsible for this effect, we determined the
CFU/mL of NCTC8325 grown overnight on TSA plates
containing 5% Medihoney or 5% manuka honey. The CFU/
mL were only slightly decreased on these plates compared to TSA
plates without honey or with 5% sugar solution (Table 2),
demonstrating that 5% Medihoney alone had no significant effect
on the growth of the bacterium on the plates (p.0.05). This result
also supports the synergistic antibacterial activity of Medihoney
and rifampicin in combination.
MGO is not Solely Responsible for Honey-rifampicin
Synergy
MGO is one of the predominant antimicrobial compounds in
manuka honey [22,23]. To investigate whether MGO responsible
for the synergistic effect in combination with rifampicin, a
checkerboard microdilution assay was performed (Table 3).
Table 1. Interaction of Medihoney and rifampicin against S. aureus by checkerboard microdilution assay.
MICRif
a (mg/ml) MIChoney
b (%[w/v]) FICI synergistic
alone comb. alone comb.
NCTC8325 Rif Medihoney 0.039 0.0024 8 3 0.45 (0.07+0.38) yes
Rif manuka 0.039 0.0024 8 3 0.45 (0.07+0.38) yes
RPAH 181 Rif Medihoney 0.078 0.0024 8 3 0.41 (0.03+0.38) yes
Rif manuka 0.078 0.0024 8 3 0.42 (0.03+0.38) yes
MW21 Rif Medihoney 0.039 0.0024 8 3 0.45 (0.07+0.38) yes
Rif manuka 0.039 0.0024 8 3 0.45 (0.07+0.38) yes
IMVS671 Rif Medihoney 0.078 0.0024 8 3 0.41 (0.03+0.38) yes
Rif manuka 0.078 0.0024 8 3 0.41 (0.03+0.38) yes
04-227-35672 Rif Medihoney 0.039 0.0024 8 3 0.45 (0.07+0.38) yes
Rif manuka 0.039 0.0024 8 3 0.45 (0.07+0.38) yes
1MRSA strain;
2clinical isolate;
aMICRif is minimum inhibitory concentration of rifampicin either alone (alone) or in combination with honey (comb.);
bMIChoney is the MIC of honey (Medihoney and manuka honey, respectively) either alone or in combination with rifampicin; Rif is rifampicin.
doi:10.1371/journal.pone.0057679.t001
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Figure 1. Enhanced antibacterial activity of rifampicin-honey combination treatment against S. aureus. (A) Time-kill curves for S. aureus
NCTC8325 in CaMHB. Bacteria were incubated in 7% Medihoney, 0.2 mg/ml rifampicin, or both. A growth control using just CaMHB is included as
indicated. Rif: rifampicin; *: below detection limit (,50 CFU/ml). (B) Filter discs containing 4 mg of rifampicin were placed on S. aureus NCTC8325
spread on TSA plates containing no honey (TSA), 5% sugar solution (sugar), 5% manuka honey, or 5% Medihoney. The shown plates were incubated
at 37uC for 24 h. Red arrows denote rifampicin resistant colonies that appeared on the TSA and sugar control plates, but not on Medihoney or
manuka honey plates. Minimum inhibitory concentrations of break-through colonies (clones 1–3) were determined against Medihoney and rifampicin
(see Fig. 4). (C) Sensitivity of different S. aureus strains to rifampicin and honey using the agar disc diffusion assay. Diameter (in mm) of zones of
inhibition around 4 mg-impregnated rifampicin discs on TSA plates without honey (red bars), and in the presence of either 5% sugar solution (blue
bars), 5% manuka honey (green bars) or 5% Medihoney (black bars).
doi:10.1371/journal.pone.0057679.g001
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MGO showed antibacterial activity against all tested S. aureus
strains, with MICs of 150–160 mg/mL. This is comparable to
MIC data reported in the literature [22,23]. These concentrations
correspond to the MGO concentration in 16–17% (w/v) of our
tested manuka honey (given that manuka honey contains 958 mg/
kg MGO). While this might seem high compared to the MIC of an
antibiotic, this ubiquitous compound, while toxic, is also beneficial
to bacterial cells [47]. Therefore, unlike antibiotics, it is unclear
how much MGO is actually harmful and the MIC for MGO may
not directly translate like antibiotics. The combination of MGO
and rifampicin was not synergistic toward any of the tested S.
aureus strains (FICI .0.5). In the presence of sugar, at the same
concentrations present in the honey experiments, the FICIs were
higher (.1), indicating that the combined effect of MGO and
rifampicin is weaker in the presence of sugar (Table 3).
The synergistic effect of MGO and rifampicin was also
examined using time-kill assays. A concentration of 70 mg/ml
MGO (corresponding to the concentration of MGO in 7% (w/v)
manuka honey) inhibited growth of S. aureus NCTC8325 for up to
8 h. However, after 8 h, growth of bacteria occurred and at 48 h,
the CFU/mL count increased to levels of growth similar to that
observed in the untreated culture (Fig. 2A). When combined with
rifampicin, an increase in the antimicrobial activity could be
detected, but after 12 h the CFU/mL count reached the level of
the no-treatment control. S. aureus isolates originating from that
sample and subsequently cultured in the presence of rifampicin
were no longer susceptible to rifampicin at all tested concentra-
tions (0–20 mg/ml) (data not shown). MGO in CaMHB medium
supplemented with sugar equivalent to that present in 7% honey
(MGOS) had reduced antimicrobial activity compared to MGO in
CaMHB (Fig. 2B).
These results demonstrate that, although MGO alone displays a
clear antibacterial activity, MGO is not the sole reason for the
antimicrobial activity of manuka honey. More importantly, while a
combinational treatment of MGO and rifampicin resulted in
increased sensitivity of S. aureus to rifampicin, unlike honey this
effect was only additive, not synergistic, and did not result in
complete inhibition of growth.
No Reversal of Rifampicin Resistance after Treatment
with Medihoney
It has been reported, that a combination of oxacillin and
manuka honey can restore oxacillin susceptibility to MRSA strains
[44]. In order to investigate, whether a combination of rifampicin
and Medihoney can reverse rifampicin resistance, an agar disc
diffusion assay was performed. The oxacillin resistant strain
RPAH18 and a rifampicin resistant NCTC8325 clone (clone 1,
refer to Fig. 1) were spread out on TSA plates or TSA plates
containing 5% Medihoney. Sub-inhibitory concentrations of
Medihoney caused the appearance of inhibition zones of 25 mm
diameter around 4 mg oxacillin discs, showing the reversal of
oxacillin resistance in presence of Medihoney. In contrast, no
inhibition zones could be detected around 4 mg rifampicin discs on
Medihoney plates (Fig. 3). Thus, unlike oxacillin, Medihoney is
not able to restore rifampicin susceptibility to S.aureus that are
already resistant to rifampicin.
Presence of Medihoney Prevents the Emergence of
Rifampicin-resistant S. aureus
The results of the time-kill experiments with S. aureus
NCTC8325 (Fig. 1A) showed that 0.2 mg/mL rifampicin
displayed antimicrobial activity. However, at 24 h the bacterial
CFU/mL was similar to levels of growth observed in the no-
treatment cultures. This strongly suggests that the bacteria had
developed the ability to grow in the presence of rifampicin. To
verify this, we tested S. aureus NCTC8325 originating from the
rifampicin treated sample (after 24 h) for susceptibility to
rifampicin by re-assessing the MIC (examined in the range of
0.0012 to 20 mg/mL rifampicin). In all experiments these bacteria
were able to grow at the highest levels of rifampicin when this
compound was added alone (data not shown). S. aureus
NCTC8325 cells originating from the sample with 7% Medihoney
were still susceptible to either rifampicin or Medihoney after 24 h
(data not shown). However, treatment of previously naive cultures
of S. aureus NCTC8325 with 0.2 mg/mL rifampicin in combination
with 7% Medihoney resulted in a complete inhibition of growth
Table 2. Effect of sub-inhibitory concentration of honey on
the growth of S. aureus NCTC8325 on agar plates.
CFU/mL (6107) % control
TSA 400 1 00
TSA +5% sugar solution 1500 375
TSA +5% manuka honey 350 88
TSA +5% Medihoney 350 88
doi:10.1371/journal.pone.0057679.t002
Table 3. Interaction of methylglyoxal and rifampicin against S. aureus by checkerboard microdilution assays.
MICRif (mg/ml) MICMGO/MGO
s (mg/ml) FICI synergistic
alone comb. alone comb.
NCTC8325 Rif Medihoney 0.039 0.0039 150 80 0.63 (0.1+0.53) no
Rif manuka 0.039 0.024 170 150 1.5 (0.62+0.88) no
RPAH 181 Rif Medihoney 0.078 0.0078 160 80 0.6 (0.1+0.5) no
Rif manuka 0.078 0.024 170 160 1.25 (0.31+0.94) no
04-227-35672 Rif Medihoney 0.039 0.0039 150 80 0.63 (0.1+0.53) no
Rif manuka 0.039 0.0024 160 140 1.5 (0.62+0.88) no
1MRSA strain;
2clinical isolate; MIC is minimum inhibitory concentration; MGO: methylglyoxal in CaMHB; MGOS: methylglyoxal in CaMHB with sugar solution (equivalent to the sugar
content of honey); Rif is rifampicin.
doi:10.1371/journal.pone.0057679.t003
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(Fig. 1A). These findings suggest that the combination of
rifampicin and Medihoney can maintain the susceptibility of
S. aureus to rifampicin, even at sub-MIC levels of Medihoney.
In the agar disc diffusion assay we observed single break-
through colonies within the zone of inhibition on rifampicin-TSA
plates and on rifampicin-TSA plates with 5% sugar solution
(Fig. 1A). Several of these colonies were isolated and tested for
susceptibility to rifampicin and honey by determining MICs as
described above. All tested clones now had a rifampicin MIC
.20 mg/mL but were still fully sensitive to Medihoney (Fig. 4A
and 4B). No colonies could be detected in the zone of clearance
on rifampicin-TSA plates containing 5% Medihoney or manuka
honey, even after 48 h incubation (data not shown), indicating that
the presence of either of these honeys either prevents survival of
break-through S. aureus colonies or prevents the attainment of
mechanisms that enhance resistance to rifampicin.
Discussion
Chronic wounds are an increasingly urgent health problem and
bacterial infection plays a significant role in the inability of these
wounds to heal [48]. Treatment of such infections often involves
combinations of antibiotics in an effort to increase efficacy and
stem antibiotic resistance. Honey has several antibacterial
components and it is this property that is likely to explain why,
unlike antibiotics, it does not induce resistance in bacteria. Here
we show conclusively that the combination of clinically-approved
manuka honey (Medihoney) and the antibiotic rifampicin has a
synergistic effect on antibacterial activity against clinical isolates of
S. aureus, including MRSA strains. We also show that MGO, a
major antimicrobial compound in manuka honey [22,23], is not
solely responsible for the synergistic action. Moreover, while
breakthrough colonies were obtained on plates containing
rifampicin, the combination of rifampicin and Medihoney
completely inhibited survival of S. aureus.
Recently, synergistic action between manuka honey and
oxacillin was reported for S. aureus [44]; and between manuka
honey and tetracycline, imipinem and mupirocin for S. aureus and
P. aeruginosa [49]. These and our data support the idea of a
combinational use of manuka honey and antibiotics for the
effective treatment of chronic wound infections, particularly in
cases where multidrug resistant organisms are present. Commer-
cially-available honey dressings are also relatively inexpensive and
non-toxic, which makes them attractive to use in combination with
antibiotics.
A very recent study suggested a synergistic activity of rifampicin
in combination with manuka honey. However, the high suscep-
tibility of the MRSA strain used to rifampicin made it difficult to
perceive increased susceptibility in the presence of honey [49].
Only one S. aureus strain, E-MRSA, was tested so we cannot rule
out a strain specific issue in this case. Our study provides strong
evidence that rifampicin in combination with maunka honey is
synergistic across a range of S. aureus strains, including clinical
isolates and MRSA.
As shown here and in previous studies, S. aureus can develop
rifampicin resistance readily [29]. However, in the presence of
sub-inhibitory concentrations of Medihoney or manuka honey, no
rifampicin resistant S. aureus were detected. Whether honey acts to
block the rifampicin resistance mechanism in S. aureus by
preventing mutations in the gene encoding its target, the b
subunit of RNA polymerase, or whether in the presence of both
honey and rifampicin the bacteria do not survive long enough to
develop resistance, remains unclear and needs further investiga-
tion. Regardless of the reason, our data here indicate that this
Figure 2. Growth curves of S. aureus NCTC8325 in CaMHB. Bacteria were incubated with (A) 70 mg/ml MGO, 0.2 mg/ml rifampicin, or both, or
with (B) 70 mg/ml MGO (in CaMHB with 7% sugar solution, MGOS), 0.2 mg/ml rifampicin, or both. A growth control using just CaMHB is included as
indicated. Rif is rifampicin.
doi:10.1371/journal.pone.0057679.g002
Synergism between Medihoney and Rifampicin
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combination treatment has potential in preventing the survival of
S. aureus due to rifampicin resistance during therapy of skin
infections and chronic wounds. In the longer term, this type of
therapy may also reduce the rate of occurrence of rifampicin
resistant bacteria in the clinic and the environment.
One of the predominant antibacterial compounds in manuka
honey is methyglyoxal (MGO, [22,23,24]), which is formed by a
non-enzymatic conversion of nectar-derived dihydroxyacetone
[50]. However, the level of MGO present in honey appears to be
considerably lower than that required to eliminate microbes
treated with MGO alone [51]. Although a synergistic interaction
between MGO and antibiotics against Pseudomonas aeruginosa has
been reported [52], we did not find this with S. aureus. MGO in
combination with rifampicin was only additive, not synergistic.
Our results demonstrate that MGO is not solely responsible for the
rifampicin-Medihoney synergistic activity. The botanical origin of
honey influences its biological activity and many different
antibacterial components have been identified in honey [53].
These components very likely interact with each other synergis-
tically, additively or even antagonistically, so when isolated may
have different effect on bacterial growth compared to their
combined effect in honey. Interestingly, in the presence of sugar
(equivalent to the sugar content of honey), the additive effect of
MGO and rifampicin was significantly decreased compared to just
MGO alone. This could be due to the growth-enhancing property
of the sugar concentrations used here, reducing the antibacterial
activity of MGO and rifampicin.
Figure 3. Reversal of oxacillin resistance but not rifampicin resistance in S. aureus by Medihoney. Oxacillin resistant MRSA RPAH18 and
rifampicin resistant clone 1 (Fig. 1) were streaked out on TSA plates containing no honey (TSA), 5% sugar solution (sugar), or 5% Medihoney.
Inhibition zones around filter discs containing 4 mg rifampicin (rif) or 4 mg oxacillin (oxa) were measured after incubation at 37uC for 24 h.
doi:10.1371/journal.pone.0057679.g003
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Various in vitro studies have shown synergistic effects between
antibiotics and plant-derived pure compounds (such as baicalin,
tellimagrandin I, epigallocatechin-gallate, or berberine;
[41,54,55,56]) or complex natural products (e.g. garlic extract;
[57,58]). However, unlike honey, none of these natural com-
pounds or products has been successfully developed for clinical use
as antibacterials. Importantly, concentrations of honey that have
synergistic activity with rifampicin (6–8%) are easily achievable at
the wound site, since typically honey dressings have honey
concentrations of .80% [59], and are unlikely to decrease to
such low concentrations even with large exudate volumes, as long
as the dressings are changed at reasonable frequency.
Jenkins and colleagues reported that manuka honey caused a
reversal of oxacillin resistance in MRSA. Treatment with 10%
manuka honey led to a down regulation of mecR1, which codes for
a two-component sensor/signal transducer protein that regulates
the expression of mecA (encoding a penicillin-binding protein that
mediates the oxacillin resistance, [44]). However, we could not
detect a reversal of rifampicin resistance after treatment with
Medihoney or manuka honey (Fig. 3). Rifampicin and oxacillin
are members of different antibiotic classes and the resistance
mechanisms are not related. Rifampicin resistance is typically due
to a single-point mutation in the rpoB gene, resulting in an amino
acid substitution in the rifampicin-binding site on RNA polymer-
ase [34,35,36]. Thus, the potential of honey to reverse oxacillin
resistance is likely related to the specific resistance mechanism
against that antibiotic.
In conclusion, our results demonstrate a synergism between
Medihoney and rifampicin against laboratory and clinical strains
of S. aureus including MRSA strains. A combination of rifampicin
and Medihoney maintained rifampicin susceptibility in S. aureus,
which was rapidly lost in the presence of rifampicin alone. Our
results support the potential of the combinational use of manuka
honey and antibiotics in the treatment of S. aureus-related skin
infections. The results of this study are encouraging, and
controlled clinical studies are needed to define the efficacy of a
Medihoney-rifampicin combination in vivo. Further study is also
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